Helius Medical Technologies, Inc. (NASDAQ:HSDT – Get Rating) saw a significant growth in short interest in December. As of December 30th, there was short interest totalling 582,000 shares, a growth of 58.7% from the December 15th total of 366,700 shares. Based on an average daily trading volume, of 760,400 shares, the short-interest ratio is currently 0.8 days.
Wall Street Analysts Forecast Growth
Separately, Maxim Group began coverage on shares of Helius Medical Technologies in a research note on Tuesday, December 20th. They set a “buy” rating for the company.
Helius Medical Technologies Trading Up 2.8 %
HSDT opened at $0.37 on Friday. The firm has a market capitalization of $10.35 million, a PE ratio of -0.10 and a beta of 1.02. The firm’s 50-day moving average price is $0.30 and its 200 day moving average price is $0.49. Helius Medical Technologies has a twelve month low of $0.20 and a twelve month high of $4.76.
Institutional Trading of Helius Medical Technologies
An institutional investor recently raised its position in Helius Medical Technologies stock. BlackRock Inc. raised its holdings in Helius Medical Technologies, Inc. (NASDAQ:HSDT – Get Rating) by 8,297.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 255,381 shares of the company’s stock after acquiring an additional 252,340 shares during the quarter. BlackRock Inc. owned 0.91% of Helius Medical Technologies worth $71,000 as of its most recent filing with the Securities and Exchange Commission. 11.77% of the stock is currently owned by institutional investors.
About Helius Medical Technologies
Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
- Get a free copy of the StockNews.com research report on Helius Medical Technologies (HSDT)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.